Fallon Medical Complex Hospital | |
202 S 4th St W, Baker, Montana 59313 | |
(406) 778-3331 | |
Not Available |
Name | Fallon Medical Complex Hospital |
---|---|
Type | Critical Access Hospital |
Location | 202 S 4th St W, Baker, Montana |
Ownership | Voluntary non-profit - Private |
Emergency Services | Yes |
Medicare ID (CCN) | 271301 |
NPI Number | 1316965346 |
Organization Name | FALLON MEDICAL COMPLEX INC |
Address | 202 South 4th Street West, Baker, MT 59313 |
Hospital Type | General Acute Care Hospital - Critical Access |
Phone Number | 406-778-3331 |
News Archive
Could a fatalistic attitude toward cervical cancer serve as a barrier to prevention of the disease? A recent study conducted by University of Kentucky researchers in the Rural Cancer Prevention Center suggests a link between fatalistic beliefs and completion of the human papillomavirus (HPV) vaccine series among a sample of young Appalachian Kentucky women.
Today the American Legacy Foundation(R) (Legacy) urged the Food and Drug Administration (FDA) to prohibit menthol in cigarettes and other flavored tobacco products as one of its first priorities related to the Family Smoking Prevention and Tobacco Control Act (the Act).
The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand.
UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.
Many cancer researchers believe that cutting-edge advances in genomics will pave the way for personalized or "precision" cancer medicine for all patients in the near future. A new study by researchers at Dana-Farber Cancer Institute, however, suggest that not all doctors are ready to embrace tests that look for hundreds of DNA changes in patients' tumor samples, while others plan to offer this type of cancer gene testing to most of their patients.
› Verified 8 days ago
Able to receive lab results electronically | Not Available |
Able to track patients' lab results, tests, and referrals electronically between visits | Not Available |
News Archive
Could a fatalistic attitude toward cervical cancer serve as a barrier to prevention of the disease? A recent study conducted by University of Kentucky researchers in the Rural Cancer Prevention Center suggests a link between fatalistic beliefs and completion of the human papillomavirus (HPV) vaccine series among a sample of young Appalachian Kentucky women.
Today the American Legacy Foundation(R) (Legacy) urged the Food and Drug Administration (FDA) to prohibit menthol in cigarettes and other flavored tobacco products as one of its first priorities related to the Family Smoking Prevention and Tobacco Control Act (the Act).
The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand.
UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.
Many cancer researchers believe that cutting-edge advances in genomics will pave the way for personalized or "precision" cancer medicine for all patients in the near future. A new study by researchers at Dana-Farber Cancer Institute, however, suggest that not all doctors are ready to embrace tests that look for hundreds of DNA changes in patients' tumor samples, while others plan to offer this type of cancer gene testing to most of their patients.
› Verified 8 days ago
Fallon Medical Complex Hospital Critical Access Hospital Location: 202 S 4th St W, Baker, Montana 59313 Phone: (406) 778-3331 |